Application of transient elastography in nonalcoholic fatty liver disease

키워드

참고문헌 (99)

1. Younossi Z, "Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 69, pp.2672~2682 (2019)
2. Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755.e3 (2019)
3. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
4. Wong VW, "Noninvasive biomarkers in NAFLD and NASH-current progress and future promise", Nat Rev Gastroenterol Hepatol, 15, pp.461~478 (2018)
5. Wong VW, "Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1 : definition, risk factors and assessment", J Gastroenterol Hepatol, 33, pp.70~85 (2018)
6. Tricò D, "Metabolic features of nonalcoholic fatty liver(NAFL)in obese adolescents : findings from a multiethnic cohort", Hepatology, 68, pp.1376~1390 (2018)
7. Castera L, "Diagnosis of non-alcoholic fatty liver disease", nonalcoholic steatohepatitis : non-invasive tests are enough, 2018, pp.38(Suppl 1), 67~70
8. Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62(1 Suppl), pp.S47~S64 (2014)
9. Bedossa P, "Pathology of non-alcoholic fatty liver disease", Liver Int, 37(Suppl 1), pp.85~89 (2017)
10. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
11. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
12. Stål P, "Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance", World J Gastroenterol, 21, pp.11077~11087 (2015)
13. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
14. Chitturi S, "Non-alcoholic fatty liver disease in the Asia-Pacific region : definitions and overview of proposed guidelines", J Gastroenterol Hepatol, 22, pp.778~787 (2007)
15. Ratziu V, "Sampling variability of liver biopsy in nonalcoholic fatty liver disease", Gastroenterology, 128, pp.1898~1906 (2005)
16. Mikolasevic I, "Transient elastography(FibroScan(®))with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease-where do we stand?", World J Gastroenterol, 22, pp.7236~7251 (2016)
17. Myers RP, "Controlled Attenuation Parameter(CAP) : a noninvasive method for the detection of hepatic steatosis based on transient elastography", Liver Int, 32, pp.902~910 (2012)
18. Sasso M, "Controlled attenuation parameter(CAP) : a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis : preliminary study and validation in a cohort of patients with chronic liver disease from various causes", Ultrasound Med Biol, 36, pp.1825~1835 (2010)
19. Sasso M, "Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®) : validation in chronic hepatitis C", J Viral Hepat, 19, pp.244~253 (2012)
20. de Lédinghen V, "Noninvasive diagnosis of liver steatosis using controlled attenuation parameter(CAP)and transient elastography", Liver Int, 32, pp.911~918 (2012)
21. Chan WK, "Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease", J Gastroenterol Hepatol, 29, pp.1470~1476 (2014)
22. Shen F, "Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients", World J Gastroenterol, 20, pp.4702~4711 (2014)
23. Chon YE, "Controlled attenuation parameter(CAP)for detection of hepatic steatosis in patients with chronic liver diseases : a prospective study of a native Korean population", Liver Int, 34, pp.102~109 (2014)
24. Mi YQ, "Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan® : validation in chronic hepatitis B", Dig Dis Sci, 60, pp.243~251 (2015)
25. Imajo K, "Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637.e7 (2016)
26. de Lédinghen V, "Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 31, pp.848~855 (2016)
27. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607.e2 (2017)
28. Chan WK, "Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?", J Gastroenterol Hepatol, 33, pp.1787~1794 (2018)
29. Garg H, "Utility of transient elastography(fibroscan)and impact of bariatric surgery on nonalcoholic fatty liver disease(NAFLD)in morbidly obese patients", Surg Obes Relat Dis, 14, pp.81~91 (2018)
30. Siddiqui MS, "Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.156~163.e2 (2019)
31. Eddowes PJ, "Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1717~1730 (2019)
32. Karlas T, "Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis", J Hepatol, 66, pp.1022~1030 (2017)
33. Springer F, "Liver fat content determined by magnetic resonance imaging and spectroscopy", World J Gastroenterol, 16, pp.1560~1566 (2010)
34. Caussy C, "Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis", Hepatology, 67, pp.1348~1359 (2018)
35. Loomba R, "Ezetimibe for the treatment of nonalcoholic steatohepatitis : assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial(MOZART trial)", Hepatology, 61, pp.1239~1250 (2015)
36. Ferraioli G, "Interobserver reproducibility of the controlled attenuation parameter(CAP)for quantifying liver steatosis", Hepatol Int, 8, pp.576~581 (2014)
37. Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
38. de Lédinghen V, "Controlled attenuation parameter(CAP)for the diagnosis of steatosis : a prospective study of 5323 examinations", J Hepatol, 60, pp.1026~1031 (2014)
39. Kwok R, "Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements : a prospective cohort study", Gut, 65, pp.1359~1368 (2016)
40. Shi KQ, "Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease : a meta-analysis of diagnostic accuracy", J Gastroenterol Hepatol, 29, pp.1149~1158 (2014)
41. Sandrin L, "Transient elastography : a new noninvasive method for assessment of hepatic fibrosis", Ultrasound Med Biol, 29, pp.1705~1713 (2003)
42. Petta S, "Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values", Hepatology, 65, pp.1145~1155 (2017)
43. Castera L, "Non-invasive evaluation of liver fibrosis using transient elastography", J Hepatol, 48, pp.835~847 (2008)
44. Ziol M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C", Hepatology, 41, pp.48~54 (2005)
45. Chan HL, "Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography(Fibroscan)for liver fibrosis in chronic hepatitis B", J Viral Hepat, 16, pp.36~44 (2009)
46. Yoneda M, "Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease(NAFLD)", Dig Liver Dis, 40, pp.371~378 (2008)
47. Wong VW, "Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease", Hepatology, 51, pp.454~462 (2010)
48. Gaia S, "Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis", J Hepatol, 54, pp.64~71 (2011)
49. Wong VW, "Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 107, pp.1862~1871 (2012)
50. Kumar R, "Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease : diagnostic performance and clinicopathological correlation", Dig Dis Sci, 58, pp.265~274 (2013)
51. Lee HW, "Discrimination of nonalcoholic steatohepatitis using transient elastography in patients with nonalcoholic fatty liver disease", PLoS One, 11, pp.e0157358~ (2016)
52. Talwalkar JA, "Ultrasound-based transient elastography for the detection of hepatic fibrosis : systematic review and meta-analysis", Clin Gastroenterol Hepatol, 5, pp.1214~1220 (2007)
53. Fraquelli M, "Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease", Gut, 56, pp.968~973 (2007)
54. Hu Z, "Using ultrasonic transient elastometry(FibroScan)to predict esophageal varices in patients with viral liver cirrhosis", Ultrasound Med Biol, 41, pp.1530~1537 (2015)
55. Wang JH, "Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus-related cirrhosis", J Gastroenterol Hepatol, 27, pp.1213~1218 (2012)
56. Pritchett S, "The optimal cut-off for predicting large oesophageal varices using transient elastography is disease specific", J Viral Hepat, 18, pp.e75~e80 (2011)
57. de Franchis R;, "Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension", J Hepatol, 63, pp.743~752 (2015)
58. Petta S, "Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis", J Hepatol, 69, pp.878~885 (2018)
59. Masuzaki R, "Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography", Hepatology, 49, pp.1954~1961 (2009)
60. Kim MN, "Risk assessment of liver-related events using transient elastography in patients with chronic hepatitis B receiving entecavir", J Clin Gastroenterol, 48, pp.272~278 (2014)
61. Chon YE, "The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B", J Clin Gastroenterol, 46, pp.518~525 (2012)
62. Singh S, "Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 11, pp.1573~1584.e1-e2 (2013)
63. Pang JX, "Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease", PLoS One, 9, pp.e95776~ (2014)
64. Liu K, "Prognostic value of controlled attenuation parameter by transient elastography", Am J Gastroenterol, 112, pp.1812~1823 (2017)
65. Ekstedt M, "Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up", Hepatology, 61, pp.1547~1554 (2015)
66. Kwok R, "Systematic review with meta-analysis : non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments", Aliment Pharmacol Ther, 39, pp.254~269 (2014)
67. Wong GL, "On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients", Antivir Ther, 16, pp.165~172 (2011)
68. Wang JH, "Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C : longitudinal study using FibroScan", J Gastroenterol Hepatol, 25, pp.964~969 (2010)
69. Koehler EM, "Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population : the Rotterdam study", Hepatology, 63, pp.138~147 (2016)
70. Stafylidou M, "Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 17, pp.1744~1755.e11 (2019)
71. Zeng J, "Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B", J Ultrasound Med, 36, pp.261~268 (2017)
72. Elsharkawy A, "Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon", J Gastroenterol Hepatol, 32, pp.1624~1630 (2017)
73. Wong GL, "Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population", J Gastroenterol Hepatol, 26, pp.300~305 (2011)
74. Wei JL, "Prevalence and severity of nonalcoholic fatty liver disease in nonobese patients : a population study using proton-magnetic resonance spectroscopy", Am J Gastroenterol, 110, pp.1306~1314 (2015)
75. Wong VW, "Transient elastography", J Gastroenterol Hepatol, 25, pp.1726~1731 (2010)
76. de Lédinghen V, "Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement : comparison between M and XL probe of FibroScan ®", J Hepatol, 56, pp.833~839 (2012)
77. Myers RP, "Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients", Hepatology, 55, pp.199~208 (2012)
78. Wong VW, "Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease", Gut, 68, pp.2057~2064 (2019)
79. Myers RP, "Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe", J Hepatol, 56, pp.564~570 (2012)
80. Boursier J, "Determination of reliability criteria for liver stiffness evaluation by transient elastography", Hepatology, 57, pp.1182~1191 (2013)
81. Loong TC, "Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 32, pp.1363~1369 (2017)
82. Wong VW, "Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter", J Hepatol, 67, pp.577~584 (2017)
83. Millonig G, "Liver stiffness is directly influenced by central venous pressure", J Hepatol, 52, pp.206~210 (2010)
84. Hopper I, "Impact of heart failure and changes to volume status on liver stiffness : non-invasive assessment using transient elastography", Eur J Heart Fail, 14, pp.621~627 (2012)
85. Millonig G, "Extrahepatic cholestasis increases liver stiffness(FibroScan)irrespective of fibrosis", Hepatology, 48, pp.1718~1723 (2008)
86. Lanzi A, "Liver AL amyloidosis as a possible cause of high liver stiffness values", Eur J Gastroenterol Hepatol, 22, pp.895~897 (2010)
87. Wong GL, "Huge adrenal hemangioma : a rare cause of deceivingly high liver stiffness measurement by transient elastography", Clin Gastroenterol Hepatol, 13, pp.e37~e38 (2015)
88. Ferraioli G, "Liver ultrasound elastography : an update to the world federation for ultrasound in medicine and biology guidelines and recommendations", Ultrasound Med Biol, 44, pp.2419~2440 (2018)
89. Arena U, "Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution", Hepatology, 58, pp.65~72 (2013)
90. Arena U, "Acute viral hepatitis increases liver stiffness values measured by transient elastography", Hepatology, 47, pp.380~384 (2008)
91. Wong GL, "Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B", J Gastroenterol Hepatol, 24, pp.1002~1007 (2009)
92. Wong VW, "Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels", Aliment Pharmacol Ther, 29, pp.387~396 (2009)
93. Petta S, "The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease", Hepatology, 62, pp.1101~1110 (2015)
94. Wong GL, "Association between anthropometric parameters and measurements of liver stiffness by transient elastography", Clin Gastroenterol Hepatol, 11, pp.295~302.e1-e3 (2013)
95. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
96. European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
97. European Association for Study of Liver, "EASL-ALEH clinical practice guidelines:non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
98. Srivastava A, "Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease", J Hepatol, 71, pp.371~378 (2019)
99. Yoneda M, "Transient elastography in patients with non-alcoholic fatty liver disease(NAFLD)", Gut, 56, pp.1330~1331 (2007)

관련 논문AI추천